Analysis of data of a clinical cancer registry for head and neck carcinoma
- Conditions
- C00-C14C32Malignant neoplasms of lip, oral cavity and pharynxMalignant neoplasm of larynx
- Registration Number
- DRKS00023378
- Lead Sponsor
- Klinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie, Universitätsklinikum Freiburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 4000
Inclusion Criteria
Head and neck carcinoma diagnoses since 2010 and registration in cancer registry
- diagnosis and therapy decision at the university hospital Freiburg
Exclusion Criteria
- Patients with other carcinomas
- Patients with tumor recurrence
- Patients who were not registered or refused to be registered in the cancer registry
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adherence to tumor board recommendations for head and neck tumor patients.
- Secondary Outcome Measures
Name Time Method Duration of therapy, overall survival,<br>recurrence-free survival in head and neck tumor patients before and after the introduction of the head and neck tumor board at Freiburg University Hospital.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular subtypes (e.g., HPV-positive, EGFR-mutant) are associated with improved survival in DRKS00023378 head and neck carcinoma registry data?
How does PD-L1 expression correlate with treatment outcomes in C00-C14 and C32 malignancies within the Freiburg University Hospital cancer registry?
What biomarkers (e.g., p16, TP53 mutations) predict response to standard-of-care therapies in head and neck squamous cell carcinoma patients from DRKS00023378?
What adverse event profiles are observed in laryngeal and pharyngeal cancer patients receiving chemoradiotherapy versus surgery in the DRKS00023378 observational study?
How do combination therapies (e.g., cetuximab + radiotherapy) compare to monotherapies in C00-C14 malignancies using real-world data from DRKS00023378?